3SBio Inc (TRSBF) Fair Value & Analysis
Healthcare · US · Market cap $5.5B · ISIN KYG8875G1029
What is 3SBio Inc really worth?
3SBio Inc
TRSBF · US
A strong business, trading 50% below our fair value of $4.30.
As of Aug 28, 2026, the fair value of 3SBio Inc is $4.30 per share against a price of $2.15, so the fair value sits 100% above the price. A model estimate blended from multiple valuation models, recalculated regularly.
Strengths
Risks
For context
Fair value as of: Aug 28, 2026
From 13 valuation models · updated 8 days ago
Fair value updated Aug 28, 2026, revised from $10.79 to $4.30 (−60.1%) since Aug 13, 2026.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The rarer combination: high quality (87/100) AND below fair value. That earns a closer look rather than a quick verdict.
- The price is below even our cautious bear case ($3.23). The market is more pessimistic than our downside scenario.
- The model range is unusually wide ($3.23 to $17.20). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year. As of Aug 28, 2026.
How to read this chart
60‑month range $0.7170 – $4.74 · fair‑value band $3.23 – $17.20 · the $2.15 price screens below the $4.30 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Aug 28, 2026.
Analysis
3SBio Inc (TRSBF) currently trades at $2.15, while our model-based Fair Value estimate is $4.30, implying the stock looks roughly 50.0% undervalued today. The Quality Score stands at 87/100 (high quality), in the Healthcare sector. Bull case: the Economic Profit group reads highest at a median of $37.50 per share, and 13 of the 13 models we run sit above the $2.15 price. Bear case: the Dividend Discount group reads lowest at $3.39, and 0 of the 13 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, 3SBio Inc generated revenue of 17.7B CNY at a net margin of 47.9%. Revenue grew 182.7% year over year. It earns a return on equity of 37.5%. The balance sheet holds a net cash position of 9.7B CNY. Fundamentals as of Aug 28, 2026
Our scenario range runs from $3.23 (bear case) to $17.20 (bull case); at $2.15, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 55% below its 52-week high and 8% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −56% fair-value upside, at 100%, TRSBF screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly $0.1936 per share, which is 4.5 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 13 models by family
Widest divergence: DCF Models ($95.69) versus Dividend Discount ($3.39). Highest evidence: Growth DCF (75).
Notify me when TRSBF reaches fair value
Put TRSBF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 28, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 85 · Market factors (momentum, volatility) 18
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
3SBio Inc., an investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People's Republic of China, the United States, and internationally.
Full company description
3SBio Inc., an investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People's Republic of China, the United States, and internationally. The company offers TPIAO bio-pharmaceutical drug for the treatment of chemotherapy-induced thrombocytopenia, immune thrombocytopenia, pediatric ITP, and chronic liver disease-related thrombocytopenia. It also provides EPIAO for indications, such as the treatment of anemia associated with chronic kidney disease, chemotherapy-induced anemia, and the reduction of allogeneic blood transfusion in surgery patients; and Yisaipu, a TNF-a inhibitor product for rheumatoid arthritis, ankylosing spondylitis, and psoriasis indications. In addition, the company offers Cipterbin, an anti-HER2 mAb for treatment of HER2-positive metastatic breast cancer in combination with chemotherapy; and Mandi, a minoxidil tincture for androgenetic alopecia and alopecia areata. Further, it develops 608, an anti-IL-17A mAb; SSS20 for patients with ITP and severe Aplastic Anemia; SSS06 for the treatment of adult dialysis patients undergoing erythropoietin therapy with a biweekly dosing interval; 613, for the treatment of acute gouty arthritis; 611, an anti-IL-4R a mAb; and 601A, an anti-VEGF mAb. Additionally, the company is involved in manufacture and sale of pharmaceutical drugs; business management; provision of technical services, investment advisory services, financial services, sports services, clinic services, technology services, and agricultural services; retail of pharmaceuticals; and enterprise management consulting. 3SBio Inc. was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
3SBio Inc reported revenue of 17.2B CNY in FY2025 versus 6.4B CNY in FY2021, a compound +28.2%/yr. Reported net income was 8.3B CNY in FY2025, compounding +49.6%/yr from FY2021.
of which total revenue +22.3 % · buybacks/dilution −0.9 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
Watch TRSBF: get an alert when its fair value changes →
Peer Group
Biotechnology · 625 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 28, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $547.55 | $278.78 | −49% |
| Regeneron Pharmaceuticals, Inc REGN | $807.71 | $594.40 | −26% |
| argenx SE ARGX | €877.60 | €292.84 | −67% |
| Samsung Biologics Co 207940 | 1,518,000 KRW | 1,055,793 KRW | −30% |
| Alnylam Pharmaceuticals, Inc ALNY | $228.61 | $51.70 | −77% |
| Royalty Pharma plc RPRX | $60.58 | $24.22 | −60% |
| Celltrion, Inc 068270 | 190,700 KRW | 74,519 KRW | −61% |
| BeOne Medicines AG ONC | $362.51 | $111.35 | −69% |
| BioNTech SE BNTX | $103.76 | $45.70 | −56% |
| Incyte Corporation INCY | $123.22 | $115.79 | −6% |
Compare 3SBio Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is 3SBio Inc (TRSBF) overvalued or undervalued?
What is the fair value of TRSBF?
What is the quality score of TRSBF?
What is the revenue of 3SBio Inc (TRSBF)?
What is the net profit margin of TRSBF?
Does 3SBio Inc pay a dividend?
Watch 3SBio Inc in the live analysis
One click puts 3SBio Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.